ライフサイエンスコーパス: maintenance dose

1 tics (at a dose equivalent to twice the oral maintenance dose).

2 loop diuretics (twice that of the oral home maintenance dose).

3 oop diuretics (dose equivalent of twice oral maintenance dose).

4 d (75 mg; n=20) or high (150 mg; n=20) daily maintenance dose.

5 ieved long-term euthyroidism off CBZ or on a maintenance dose.

6 at decreased iPTH by at least 30% became the maintenance dose.

7 the study drug or administration of the last maintenance dose.

8 kinetic parameters and calculate the optimum maintenance dose.

9 sing an optimal higher dose than the current maintenance dose.

10 g than 100-mg extended-release buprenorphine maintenance dose.

11 were explored for associations with reaching maintenance dose.

12 determine factors associated with reaching a maintenance dose.

13 ophils, sputum EoP numbers or the prednisone maintenance dose.

14 ly with both prasugrel and ticagrelor LD and maintenance dose.

15 ORC1 have been associated with acenocoumarol maintenance dose.

16 ed less than 60 kg received a 5-mg prasugrel maintenance dose.

17 val were similar at both induction doses and maintenance doses.

18 d monthly for 30 months after achievement of maintenance doses.

19 ocaine self-administration across a range of maintenance doses.

20 rogenic lipoprotein levels with twice-yearly maintenance dosing.

21 200 mg given every second week thereafter as maintenance dosing.

22 nts were updosed weekly, followed by monthly maintenance dosing.

23 during dose escalation and after 6 months of maintenance dosing.

24 ntly high reactivity with clopidogrel 150-mg maintenance dosing.

25 primary PCI cohort) continued taking an oral maintenance dose (0.5 mg, 1.0 mg, or 2.5 mg per day), an

26 uld enroll in the OLE to receive eculizumab (maintenance dose = 1,200 mg/2 weeks, after a blinded ind

27 eks, followed by the participant's choice of maintenance dose: 1.5 mg/kg once weekly, 3 mg/kg every 2

28 an intravenous loading dose (800 mg) plus 5 maintenance doses (200 mg every 12 hours) of gavestinel

29 phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily; n = 47) or phenytoin (

30 ore the impact of continued PTAH therapeutic maintenance dosing (300 mg/day) on efficacy, safety/tole

31 n via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or

32 ts who lost response could be treated with a maintenance dose 5 mg/kg higher.

33 eks (16 weeks of dose escalation; 4 weeks of maintenance dose), 803 participants (89.0%) who reached

34 d 6, and then treatment was continued with a maintenance dose administered every 4 to 8 weeks.

35 trastuzumab (50 mg/kg loading dose, 25 mg/kg maintenance dose, administered intraperitoneally twice a

36 d with a dose escalation phase followed by a maintenance dose administration.

37 children aged 5-12 years, the initial daily maintenance doses advised were 25 mg/kg for valproate an

38 ged between 5 and 12 years the initial daily maintenance doses advised were lamotrigine 1.5 mg/kg twi

39 g postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary interventio

40 rformed significantly better than the 100-mg maintenance dose among participants who used fentanyl da

41 cation had blood sampling in the morning pre-maintenance dose and again 2 h post-dose.

42 ed analyses, both Cox regression with median maintenance dose and landmark techniques showed that, in

43 the OIT group, with 67% achieving the daily maintenance dose and meeting the primary endpoint.

44 on warfarin (n = 83) or fluindione (n = 35) maintenance dose and the influence of these factors on t

45 plications for the alteration in clopidogrel maintenance dose and use of glycoprotein IIb/IIIa inhibi

46 r p 1 (when reported) were 0.8 to 70 mug for maintenance doses and 60 to 23,695 mug for cumulative do

47 (when reported) ranged from 7 to 30 mug for maintenance doses and 60 to 420 mug for cumulative doses

48 irs, 13% involved bolus dosing, 49% involved maintenance dosing, and 38% did not include exposure to

49 r and the effects on immune cells at varying maintenance doses are unknown.

50 erlying statistical interaction with aspirin maintenance dose as a possible explanation for the regio

51 ed patients with myocardial infarction, high-maintenance-dose aspirin was associated with similar rat

52 4 mg/kg intravenously, followed by a 2-mg/kg maintenance dose at weekly intervals.

53 re are no major metabolic differences on low maintenance doses between FK-506 and CsA.

54 nd 64% of the patients attained their CsA-ME maintenance dose by study week 4.

55 after week 4, were higher than those of 10mg maintenance dose cases, but no significant difference wa

56 of LA cabotegravir of 41%-46% for the first maintenance dose coadministered with 600 mg once-daily o

57 A weekly maintenance dose consisted of 200 mg or 300 mg; the lowe

58 train (rDEN3Delta30) on the day of the first maintenance dose (day 1).

59 iotic pretreatment and compared two modes of maintenance dose delivery, capsules versus enema, in a r

60 Compared with no iron, maintenance dosing did not associate with increased risk

61 e on chronic methadone should continue their maintenance dose during the perioperative period.

62 tely once every 2 weeks, followed by monthly maintenance doses during a treatment period of about 3 m

63 bleeding with prasugrel should focus on the maintenance dose (e.g., reduction in maintenance dose in

64 loading dose of VX-548, followed by a 50-mg maintenance dose every 12 hours (the high-dose group); a

65 loading dose of VX-548, followed by a 30-mg maintenance dose every 12 hours (the middle-dose group);

66 8 (a 20-mg loading dose, followed by a 10-mg maintenance dose every 12 hours); oral hydrocodone bitar

67 s phase 3b trial received emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks and are cont

68 2.0 g/kg induction dose followed by 1.0 g/kg maintenance doses every 3 weeks.

69 on dose and then either 0.5, 1.0 or 2.0 g/kg maintenance doses every 3 weeks.

70 rerandomization, in a 1:2 ratio, to receive maintenance dosing every 4 weeks or every 8 weeks to wee

71 d on experimental days 2 and 6 after the MPD maintenance dose followed by 3 days of washout.

72 300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day) for 6-12 mon

73 ew protocol (1000-mg load followed by 500-mg maintenance dose for patients <70 kg, 1250-mg followed b

74 Loading doses were given for 5 days and maintenance doses for 21 days.

75 rel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months.

76 ated the full dose at day 1 and received the maintenance dose from the start at home.

77 engineered from eculizumab, allows extending maintenance dosing from every 2-3 weeks to every 4-8 wee

78 mab (intravenous 840 mg loading dose, 420 mg maintenance doses; group A); or trastuzumab and pertuzum

79 /- 500 grains/m(3) , then randomized to four maintenance dose groups of rBet v 1-FV and one placebo g

80 The target maintenance dose had no effect on the primary outcome, b

81 Fifty-five (72%) patients reached the maintenance dose (HD) during therapy.

82 rotein or, alternatively, a lower individual maintenance dose (IMD), by OIT up-dosing.

83 gression (SVR) to the prediction of warfarin maintenance dose in a cohort of African Americans.

84 RC1 previously associated with acenocoumarol maintenance dose in a Genome-Wide Association study (GWA

85 acranial haemorrhage (ICH) and acenocoumarol maintenance dose in a Spanish population.

86 on the maintenance dose (e.g., reduction in maintenance dose in previously reported high-risk subgro

87 as to assess the functional impact of a high maintenance dose in T2DM patients with suboptimal clopid

88 by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 w

89 cyclosporine dosing patterns over the years, maintenance doses in 1469 living donor and 1486 cadaver

90 udesonide-formoterol in addition to the four maintenance doses in the SMART group or more than 16 act

91 300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 patients undergoing nonurgent PC

92 Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no

93 er donor graft recipients, the mean 12-month maintenance dose increased from 6.4 mg/kg per day in 198

94 y with BV given weekly x 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly).

95 umab (840 mg loading dose followed by 420 mg maintenance doses, intravenous; TCHP), or group B, where

96 this model predicts accurately the effective maintenance dose is currently being investigated.

97 Determining the optimal methadone maintenance dose is time consuming; currently, no biomar

98 For maintenance dosing, LBW seems to be a more appropriate d

99 portion of responders was higher with higher maintenance doses, logistic regression analysis showed t

100 The 300-mg maintenance dose may perform better among individuals wi

101 phase and delaying the administration of the maintenance dose may reduce SR and increase the reached

102 d at the beginning and just before the first maintenance dose (MD) of 100 mug of ultra-rush VIT (day

103 ) followed by a ticagrelor 90-mg twice-daily maintenance dose (MD), aspirin-treated patients (N = 110

104 placebo loading dose (LD)/clopidogrel 75 mg maintenance dose (MD), placebo LD/prasugrel 10 mg MD, or

105 tanyl (loading dose [LD] 50 micrograms kg-1, maintenance dose [MD] 2 micrograms kg-1 min-1), or high-

106 w dose (40-mg loading dose followed by 10-mg maintenance dose), medium dose (200 mg followed by 50 mg

107 mine the feasibility of reaching the maximum maintenance dose (MMD) of 5000 mg peanut protein or, alt

108 e [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks.

109 received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-m

110 -1) bolus & subsequent 50 mug kg(-1) min(-1) maintenance dose; n = 10).

111 f children with peanut anaphylaxis reached a maintenance dose of 0.25-5 g, only 21.1% reached the MMD

112 Patients received a maintenance dose of 1.0 mg/0.02 ml of intravitreal ganci

113 y subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo.

114 Aspirin desensitization with a maintenance dose of 100 mg daily has a positive impact o

115 lled aspirin desensitization protocol with a maintenance dose of 100 mg daily.

116 OIT with 2-weekly updosing until reaching a maintenance dose of 1000 mg (four large peanuts).

117 TID for 2 weeks) followed by the randomized maintenance dose of 15 or 20 mg BID for 2 more weeks.

118 ered twice daily for 24 hours, followed by a maintenance dose of 200 mg twice daily for 20 days, with

119 The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose = HD).

120 domly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every

121 escalating doses from 50 mg/d to the target maintenance dose of 300 mg/d in weeks 6 to 12, combined

122 ours for a total of six doses, followed by a maintenance dose of 400 U per kilogram three times per w

123 a patients) was well-tolerated and a loading/maintenance dose of 400/200 mg was selected for combinat

124 Twelve subjects then reached the maximum maintenance dose of 4000 mg peanut flour per day in a me

125 rtuzumab with a loading dose of 840 mg and a maintenance dose of 420 mg on day 1.

126 namic (PD) response to the reduced prasugrel maintenance dose of 5 mg in very elderly (VE) patients (

127 Then, the maintenance dose of 500 JAU was administered at 9 or 10

128 ith an initial loading dose of 8 mg/kg and a maintenance dose of 6 mg/kg on day 1, as well as intrave

129 immunological response, and tolerability, a maintenance dose of 80 mug of rBet v 1-FV appears to be

130 tients undergoing cardiac surgery while on a maintenance dose of aspirin and clopidogrel (n=45), pras

131 The optimal maintenance dose of aspirin desensitization to prevent n

132 east 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were a

133 A 150-mg maintenance dose of clopidogrel is associated with enhan

134 stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C

135 ed with clopidogrel is associated with a low maintenance dose of concomitant aspirin.

136 The mean maintenance dose of corticosteroids was slightly lower i

137 6% for each incremental increase of 1 mg/kg maintenance dose of cyclosporine (within the dose range

138 nd randomized 1:1 to receive mOIT to a total maintenance dose of either 300 or 1200 mg total protein,

139 Recent evidence has shown that a single maintenance dose of heroin attenuates psychophysiologica

140 glustat 15 mg once-daily in combination with maintenance dose of imiglucerase enzyme replacement ther

141 The mean (+/- SD) maintenance dose of LEF was 19.6 +/- 1.99 mg/day in year

142 me of subjects assigned to a standard or low maintenance dose of lithium.

143 rom the hospital the following day, with the maintenance dose of one whole egg to be taken daily.

144 Both the loading dose and maintenance dose of prasugrel were superior to clopidogr

145 te more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant rec

146 linical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.

147 We aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on coron

148 The mean (+/-SE) maintenance dose of warfarin differed significantly amon

149 (aged >/=18 years) who were taking a stable maintenance dose of warfarin were obtained at Internatio

150 placebo, 1.5 mg dulaglutide, or retatrutide maintenance doses of 0.5 mg, 4 mg (starting dose 2 mg),

151 ercutaneous coronary revascularization, with maintenance doses of 10 or 20 mg of xemilofiban or place

152 ted with 300 mg of rilonacept and then given maintenance doses of 100 mg/week.

153 nhaled corticosteroids (ICS) to define daily maintenance doses of 100 to 250 mug, >250 to 500 mug, an

154 Maintenance doses of 13-cis-retinoic acid were then admi

155 p 1), 1 loading dose of 750 mg followed by 9 maintenance doses of 150 mg (group 2), or 10 doses of 37

156 weekly amycretin escalated from 0.3 mg up to maintenance doses of 20 mg for a total treatment duratio

157 lock-randomized 1:1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinde

158 mens: 1 loading dose of 750 mg followed by 9 maintenance doses of 500 mg (group 1), 1 loading dose of

159 enously (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg) or subcutaneously (600 mg)

160 at a dose of 540,000 IU followed by monthly maintenance doses of 90,000 IU for 5 months.

161 inistration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) >100 mg/daily.

162 This study evaluated whether higher maintenance doses of buprenorphine and methadone are sup

163 Maintenance doses of clopidogrel for 4 treatment periods

164 ed seventy-eight patients were randomized to maintenance doses of either 50 mug (90 patients) or 100

165 equirement while the patient is treated with maintenance doses of immunomodulatory or immunosuppressi

166 Further studies of different maintenance doses of intravenous immunoglobulin in chron

167 Maintenance doses of lorazepam 0.02+/-0.01 mg/kg/hr, mid

168 he relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIM

169 Mean daily maintenance doses of prednisone and mycophenolate mofeti

170 Cumulative and maintenance doses of prednisone and time elapsed since t

171 e, followed by up to 14 additional 12-hourly maintenance doses of rivipansel or placebo, in addition

172 Animals received the corresponding maintenance doses of the antiplatelet agents during the

173 priming dose at 1 mg/kg on day 1 followed by maintenance doses of up to 45 mg/kg weekly.

174 In the groups receiving maintenance doses of ustekinumab every 8 weeks or every

175 Patients who required larger weekly maintenance doses of warfarin were less likely to have a

176 ic variants have been shown to require lower maintenance doses of warfarin, but a direct association

177 luate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and

178 t-based intravenous ravulizumab on day 1 and maintenance doses on day 15, then once every 8 weeks.

179 ive prasugrel (60 mg loading dose [LD]/10 mg maintenance dose once daily) or ticagrelor (180 mg LD/90

180 grel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose

181 g/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastu

182 b (8 mg/kg loading dose, followed by 6 mg/kg maintenance doses) or the fixed-dose combination of pert

183 loading dose then 15 mg/kg every 2 weeks for maintenance dosing) or placebo infusions every 2 weeks,

184 ished variants associated with acenocoumarol maintenance dose (p < 0.05).

185 priming dose; part B, to determine a weekly maintenance dose; part C, to study a loading dose in wee

186 fined daily statin dose (the assumed average maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.8

187 In post hoc analyses, the 300-mg maintenance dose performed significantly better than the

188 rcutaneous coronary intervention entered the maintenance-dose phase, a 28-day crossover comparison of

189 During the maintenance-dose phase, IPA with 20 mumol/L ADP was high

190 mab (840 mg loading dose, followed by 420 mg maintenance doses) plus intravenous trastuzumab (8 mg/kg

191 n; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in th

192 lobulin and casein are associated with lower maintenance dose reached.

193 before OIT start were associated with lower maintenance dose reached.

194 A lower maintenance dose reduces the risk of repeated reactions,

195 fety and efficacy of adalimumab double-blind maintenance dosing regimens following open-label inducti

196 which were durable over 56 weeks, with both maintenance dosing schedules (every 4 weeks and every 8

197 the effects of treatment withdrawal, and two maintenance dosing schedules over 56 weeks.

198 Under each maintenance dose, six experimental sample and choice ses

199 and CYP2C9 are associated with acenocoumarol maintenance dose, stroke recurrence and ICH in a Spanish

200 8 weeks, or 1.25 mg for a total of 20 weeks (maintenance dose sustained for the last 12 weeks).

201 ubsequent groups, patients were treated with maintenance doses that ranged from 3 to 45 mg/kg, and mo

202 ith elinogrel up to 6 hours after daily oral maintenance dosing, these differences were not statistic

203 nance over 22 to 40 weeks, followed by daily maintenance dosing through month 28.

204 ded with deuterated water, followed by daily maintenance doses throughout the intervention.

205 se of 9 MU and a 9-MU twice-daily fractioned maintenance dose, titrated on renal function.

206 hese changes include lowering the prednisone maintenance dose to maximum 0.3 mg/kg per day, raising t

207 e once daily) or ticagrelor (180 mg LD/90 mg maintenance dose twice daily) for 1 week.

208 eight) or placebo intravenously, followed by maintenance doses until delivery or 34 weeks of gestatio

209 No maximum tolerated dose was reached with maintenance doses up to 45 mg/kg.

210 Mean maintenance dose varied significantly among the 6 genoty

211 o significant differences were found between maintenance dosing via capsules versus enema.

212 of higher daily buprenorphine and methadone maintenance doses vs lower doses for reducing illicit op

213 current treatment efficacy study, the target maintenance dose was randomized to either 50 mug or 100

214 Maintenance dosing was stopped completely on day 38.

215 (Prasugrel/Clopidogrel Maintenance Dose Washout Study; NCT01014624).

216 esponses (adenosine diphosphate 20 muM) post-maintenance dose were 44+/-15% for clopidogrel and 28+/-

217 89.0%) who reached the 2.4-mg/wk semaglutide maintenance dose were randomized (2:1) to 48 weeks of co

218 aged 12 years or older, the initial advised maintenance doses were 500 mg twice per day for levetira

219 s aged 12 years or older the initial advised maintenance doses were lamotrigine 50 mg (morning) and 1

220 After initial maintenance doses were reached, doses were adjusted down

221 l trial, both extended-release buprenorphine maintenance doses were well tolerated and effective amon

222 Both maintenance doses were well tolerated with no new safety

223 ys and Ctrough, 28th day following the first maintenance dose when coadministered with rifampicin.

224 le of only 1 week was applied to achieve the maintenance dose which was administered monthly during t

225 t period of time on an as-needed basis, with maintenance dosing, which provides smaller amounts of ir

226 (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Mode

227 Groups A and C received standard maintenance dosing with tacrolimus (TAC), mycophenolate

228 ng protocol (1000-mg load followed by 500-mg maintenance dose, with doses infused during the last hou

229 ved 1-day PN/WN/CSH rush OIT plus 3 weeks of maintenance dosing, with or without 3 weeks prior and 3

230 ng schedules because it allows achieving the maintenance dose within a shorter time interval.